logo-loader
Sareum Holdings PLC

Additional disclosure concerning Michael Owen

/**/ p{margin-right:18.0pt;margin-left:0cm;font-size:8.5pt;font-family:"Verdana","sans-serif";color:black;}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .z{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.z{}table.av{border-collapse:collapse}tr.ao{page-break-inside:avoid}td.ar{width:223.2pt;padding:0cm 5.4pt 0cm 5.4pt}p.aw{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt; margin-left:0cm;text-align:justify;line-height:115%}span.at{font-size: 11.0pt;line-height:115%;font-family:"Calibri","sans-serif"}p.ax{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;line-height: 115%; margin-bottom: 6.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 0cm; text-align: right}span.aq{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"}p.ay{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;font-weight: bold; line-height: normal; margin-bottom: 6.0pt; text-align: center} span.am{color:black}p.az{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;line-height: normal; margin-bottom: 6.0pt; text-align: center}p.ba{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;margin-bottom:6.0pt;text-align:justify;line-height: normal}p.bb{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt; margin-left:0cm;text-align:justify}p.bc{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;font-weight: bold; margin-bottom: 6.0pt; text-align: justify}table.bd{width:416.25pt}tr.ad{height:17.0pt}td.af{width:274.5pt;padding:0cm 0cm 0cm 0cm;height:17.0pt}p.be{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;font-weight: bold; line-height: normal; margin-bottom: 6.0pt; text-align: justify}td.ae{width:5.0cm;padding:0cm 0cm 0cm 0cm;height:17.0pt} td.ac{width:416.25pt;padding:0cm 0cm 0cm 0cm; height:17.0pt}p.bf{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;margin-bottom:6.0pt;line-height:normal} /**/
RNS Number : 0933H
Sareum Holdings PLC
29 July 2019
 

(AIM: SAR)

29 July 2019

 

Sareum Holdings plc

("Sareum" or "the Company")

Additional disclosure concerning Michael Owen

 

Sareum Holdings PLC, the specialist small molecule drug development business, announced on 13 November 2018 the appointment of Michael Owen as a Non-Executive Director of the Company.

It has come to Sareum's attention that whilst his former directorship of BliNK Biomedical SAS ("BliNK") was detailed in that announcement, his former directorship of BliNK's subsidiary Blink Therapeutics Limited during the five years prior to that announcement should also have been included.

 

For further information, please contact: 

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

WH Ireland Limited (Nominated Adviser)

Chris Fielding / James Sinclair-Ford

020 7220 1666

Hybridan LLP (Nominated Broker)

 

Claire Noyce

020 3764 2341

Citigate Dewe Rogerson (Media enquiries)

 

Shabnam Bashir/ Mark Swallow/ David Dible

020 7638 9571

 

- Ends -


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RDNEKLFLKDFLBBQ

Quick facts: Sareum Holdings PLC

Price: £0.00

Market: AIM
Market Cap: £11.01 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Sareum's Tim Mitchell upbeat after 'very successful' early-stage cancer trial

Sareum Holdings PLC (LON:SAR) chief executive Tim Mitchell caught up with Proactive London's Andrew Scott to discuss some preliminary efficacy data released on a drug that Sareum helped to develop. Of particular note was the impact SRA737 had in combination with a common chemotherapy...

on 3/6/19